Show Search Form

Search Results

human indexable	true false
published	true false
registered interest	true false
answer date	exactly: or between: and
date	exactly: or between: and
date tabled	exactly: or between: and
ddp created	exactly: or between: and
answering body
question status
answering dept id
answering dept short name
answering dept sort name
ddp modified
hansard heading
house id
identifier
legislature	pref label
parliament number
question first answered
question text
session
session number
tabling member constituency
tabling member printed
title
type
uin
version
written parliamentary question type
answer	is ministerial correction true false
creator	label
publisher	pref label
tabling member	label

Search

818607

	human indexable
	published
	registered interest
	answer date	22/01/2018
	date	08/01/2018
	date tabled	08/01/2018
	ddp created	08/01/2018 22:35:09
	answering body	Department of Health
	question status	Tabled
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	ddp modified	08/01/2018 22:45:21 18/01/2018 12:55:02
	hansard heading	Mefloquine
	house id	2
	identifier	HL4484
	legislature	25277 pref label House of Lords
	parliament number	57
	question first answered	18/01/2018 12:23:37
	question text	To ask Her Majesty's Government, further to the Written Answer by Lord O'Shaughnessy on 22 December 2017 (HL4314), whether they consider suicide, as listed in the current mefloquine product information as a psychiatric adverse reaction, to be a permanent adverse reaction.
	session	2017/19
	session number	1
	tabling member printed	The Countess of Mar
	title	House of Lords Tabled Parliamentary Question 2017/19 HL4484
	type	WrittenParliamentaryQuestion
	uin	HL4484
	version	1
	written parliamentary question type	Ordinary
	answer	answer is ministerial correction
	creator	1861 label Biography information for The Countess of Mar
	publisher	25277 pref label House of Lords
	tabling member	1861 label Biography information for The Countess of Mar

818610

	human indexable
	published
	registered interest
	answer date	22/01/2018
	date	08/01/2018
	date tabled	08/01/2018
	ddp created	08/01/2018 22:35:15
	answering body	Department of Health
	question status	Tabled
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	ddp modified	08/01/2018 22:45:27 18/01/2018 12:23:02
	hansard heading	Levonorgestrel: Prices
	house id	2
	identifier	HL4487
	legislature	25277 pref label House of Lords
	parliament number	57
	question first answered	18/01/2018 12:22:42
	question text	To ask Her Majesty's Government whether they intend to investigate the pricing of levonorgestrel by pharmacies.
	session	2017/19
	session number	1
	tabling member printed	Lord Myners
	title	House of Lords Tabled Parliamentary Question 2017/19 HL4487
	type	WrittenParliamentaryQuestion
	uin	HL4487
	version	1
	written parliamentary question type	Ordinary
	answer	answer is ministerial correction
	creator	3869 label Biography information for Lord Myners
	publisher	25277 pref label House of Lords
	tabling member	3869 label Biography information for Lord Myners

818756

	human indexable
	published
	registered interest
	answer date	10/01/2018
	date	08/01/2018
	date tabled	08/01/2018
	ddp created	08/01/2018 23:48:15
	answering body	Department of Health
	question status	Tabled
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	ddp modified	08/01/2018 23:58:09 16/01/2018 16:51:07
	hansard heading	High Weald Lewes Havens Clinical Commissioning Group
	house id	1
	identifier	121520
	legislature	25259 pref label House of Commons
	parliament number	57
	question first answered	16/01/2018 16:19:44
	question text	To ask the Secretary of State for Health, with reference to the Answer of 8 November 2016 to Question 51429, if he will publish a copy of the validated analysis of costs provided by Coperforma Ltd to the High Weald Havens Clinical Commissioning Group referred to in that Answer; what the value is of invoices the High Weald Havens Clinical Commissioning Group received directly from each trust which incurred private ambulance costs arising from performance problems with Patient Transport Services provided by Coperforma and arms length driver operatives; and if he will make a statement.
	session	2017/19
	session number	1
	tabling member constituency	Brighton, Pavilion
	tabling member printed	Caroline Lucas
	title	House of Commons Tabled Parliamentary Question 2017/19 121520
	type	WrittenParliamentaryQuestion
	uin	121520
	version	1
	written parliamentary question type	Ordinary
	answer	answer is ministerial correction
	creator	3930 label Biography information for Caroline Lucas
	publisher	25259 pref label House of Commons
	tabling member	3930 label Biography information for Caroline Lucas